# Supplementary Table 1

Summary of case reports showing early relapses after discontinuation of N/R published as of July 1, 2022. Time is calculated from the day of the first positive test (either antigen assay or PCR). RA: rheumatoid arthritis; CD: Chron’s disease; HCQ: hydroxychloroquine; MMF: mycophenolate mofetil; LFA: lateral flow assay.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **country** | **Age /gender** | **vaccine doses (months since last)** | **comorbidities (selected medications)** | **method (Ct) at diagnosis/negativization** | **Paxlovid® days** | **day of symptom and virological relapse** | **method (Ct) at relapse** | **hospitalization** | **day of negativization (method)** | **viral sequences to exclude reinfection or mutations** | **viral isolation at relapse** | **evidence of transmission** | **ref** |
| USA | 71/M | 1 (-3) | asthma (fluticasone, albuterol) | LFA/LFA | 0-4 | 9 | PCR (19) | n.a. | 16 (LFA), 18 (PCR) | Y | N | N |  [61] |
| USA | 69/M | 2 (-4) | none | LFA/LFA | 1-5 | 10 | PCR (26) | n.a. | 14 (PCR) | Y | N | N |
| USA | 50/F | 1 (-5) | PCR (20)/LFA | 2-6 | 9 | PCR (22) | n.a. | 13 (PCR) | Y | N | N |
| USA | 63/M | 1 (-6) | LFA/LFA | 1-5 | 11 | LFA | n.a. | n.a. | N | N | Y |
| USA | 31/F | 1 (-6) | LFALFA | 0-4 | 9 | LFA | n.a. | 16 (LFA) | N | N | N |
| USA | 84/M | 1 (-6) | LFA/LFA | 1-5 | 13 | LFA | n.a. | 18 (LFA) | N | N | N |
| USA | 47/F | 1 (-4) | LFA/LFA | 1-5 | 12 | LFA | n.a. | 18 (LFA) | N | N | N |
| USA | 55/M | 1 (-5) | LFA/PCR | 0-4 | 10 | PCR (17) | n.a. | 18 (PCR) | N | N | N |
| USA | 67/M | 2 (-0.5) | LFA/LFA | 2-6 | 12 | LFA | n.a. | 22 (LFA) | N | N | N |
| USA | 68/F | 2 (1) | LFA/LFA | 2-6 | 11 | LFA | n.a. | 18 (LFA) | N | N | Y |
| Italy | 63/M | 3 (-5) | obesity, SAH, AMI | PCR (21)/PCR | 1-5 | 12 | 17 | N | 24 | Y | N | N | [62] |
| Italy | 64/M | 3 (-8) | lung cancer | PCR (35)/PCR | 2-6 | 10 | 22 | N | 28 | Y | N | N |
| USA | n.a. | n.a. (n.a.) | n.a. | LFA/n.a. | 5-9 | 9 | n.a. | n.a. | 14-20 | Y (post) | Y (up to 16) | N | [63] |
| USA | Y (post) | Y (up to 16) | N |
| USA | Y (post) | Y (up to 10) | N |
| USA | Y (post) | N | N |
| USA | Y (post) | N | N |
| USA | Y (post) | N | N |
| USA | N (post) | N | N |
| USA | n.a. | 3 (n.a.) | n.a. | n.a. | n.a. | n.a. | PCR | N | n.a. | Y | Y | N | [64] |
| USA | n.a./Mn.a./Mn.a./Mn.a./Fn.a./Fn.a./F | 3 (n.a.) | n.a. | n.a. | 1/4 – 5/9 | 11-15 | n.a. | N | n.a. | Y | Y | N | [66] |
| USA | 3 (n.a.) | N | Y | N | N |
| USA | 3 (n.a.) | N | Y | N | N |
| USA | 3 (n.a.) | N | Y | N | N |
| USA | 3 (n.a.) | N | Y | N | N |
| USA | 3 (n.a.) | N | Y | N | N |
| UK | 55/M | “full course” (n.a.) | RA, vasculitis (rituximab, prednisolone) | LFA/LFA | 2-6 | 8 | LFA | N | n.a. | N | N | N | [65] |
| UK | 44/F | “full course” (n.a.) | CD (ustekinumab) | LFA/LFA | 4-9 | 14 | LFA | N | n.a. | N | N | N |
| UK | 59/F | n.a. (n.a.) | vasculitis (rituximab, MMF, prednisolone, HCQ) | LFA/LFA | 2-7 | 19 | LFA | N | n.a. | N | N | N |
| Saudi Arabia | 87/M | 2 (-12)  | hypertensionand RA (no immunosupression) | n.a./.a. | 0-4 | 11 | n.a. | Y | n.a. | N | N | N | [67] |
| Saudi Arabia | 72/M | 2 (-14) | RA (no immunosuppression) and TIA | n.a. | 0-4 | 14 | n.a. | Y | n.a. | N | N | N |
| USA | 81/M | 4 (n.a.) | n.a. | n.a. | 0-4 | 8 | n.a. | N | n.a. | N | N | N | [69] |
| USA | 79/M | 4 (-4) | n.a. | n.a. | 0-4 | 8 (no symptoms | n.a. | N | n.a. | N | N | N | [100] |